StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) income statement

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$2.81−0.10 (-3.44%)

Close on Nov 20, 2026Market cap $255.67MP/E –Yield –

See a number that looks wrong?